Inspire Medical Systems sells a single commercial implant franchise whose near-term growth has been interrupted by coding and reimbursement confusion around the Inspire V system. The interruption is administrative rather than clinical. Centers still implant a closed-loop hypoglossal-nerve stimulator for moderate-to-severe obstructive sleep apnea after continuous positive airway pressure fails. What changed is the billing path that hospitals, ambulatory surgery centers, and surgeons use to get paid. Until that path is stable, procedure volume is the constraint, not product acceptance.
Second-quarter revenue fell 7.6% to $200.6 million. Gross margin expanded as the Inspire V mix rose. Operating cash flow improved to $23.2 million. Management raised the full-year sales range after the quarter exceeded internal expectations. The company still guides to a year of contraction versus 2025. Project Horizon reallocates spending toward patient flow rather than declaring that demand has already returned.
The listed parent is a Delaware corporation on the New York Stock Exchange under INSP, not a Nasdaq development-stage issuer. The EDGAR registrant file confirms that identity. Cash and investments of $415.2 million and the absence of funded debt give the company time to work the coding problem. The equity still prices a recovery in procedure volume that has not yet appeared in reported sales.
The investment question is whether center education, proposed facility-rate increases, and a possible later permanent procedure code restore growth before competitors and weight-loss drugs take share. A cheaper multiple on last year's sales is not proof that volumes have bottomed. The next useful evidence is sequential U.S. procedure recovery, not another explanation of why billing remains difficult.